BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 25257607)

  • 1. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.
    Borsi E; Terragna C; Brioli A; Tacchetti P; Martello M; Cavo M
    Transl Res; 2015 Jun; 165(6):641-50. PubMed ID: 25553605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.
    Borsi E; Perrone G; Terragna C; Martello M; Dico AF; Solaini G; Baracca A; Sgarbi G; Pasquinelli G; Valente S; Zamagni E; Tacchetti P; Martinelli G; Cavo M
    Oncotarget; 2014 Apr; 5(7):1779-92. PubMed ID: 24732040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
    Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
    Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
    Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
    Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
    Greenberger LM; Horak ID; Filpula D; Sapra P; Westergaard M; Frydenlund HF; Albaek C; Schrøder H; Ørum H
    Mol Cancer Ther; 2008 Nov; 7(11):3598-608. PubMed ID: 18974394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.
    Storti P; Bolzoni M; Donofrio G; Airoldi I; Guasco D; Toscani D; Martella E; Lazzaretti M; Mancini C; Agnelli L; Patrene K; Maïga S; Franceschi V; Colla S; Anderson J; Neri A; Amiot M; Aversa F; Roodman GD; Giuliani N
    Leukemia; 2013 Aug; 27(8):1697-706. PubMed ID: 23344526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of hypoxia-inducible factor-1 alpha reduces proliferation, induces apoptosis and attenuates the aggressive phenotype of retinoblastoma WERI-Rb-1 cells under hypoxic conditions.
    Xia T; Cheng H; Zhu Y
    Ann Clin Lab Sci; 2014; 44(2):134-44. PubMed ID: 24795051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow derived stromal cells modified by adenovirus-mediated HIF-1alpha double mutant protect cardiac myocytes against CoCl2-induced apoptosis.
    Wang Y; Sun A; Xue J; Feng C; Li J; Wu J
    Toxicol In Vitro; 2009 Sep; 23(6):1069-75. PubMed ID: 19520152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1α and promotes cancer cell proliferation.
    Jeon YK; Park SG; Choi IW; Lee SW; Lee SM; Choi I
    Biochem Biophys Res Commun; 2015 Apr; 459(2):277-283. PubMed ID: 25725157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
    Martin SK; Diamond P; Gronthos S; Peet DJ; Zannettino AC
    Leukemia; 2011 Oct; 25(10):1533-42. PubMed ID: 21637285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor-1α signalling.
    Park SY; Nho CW; Kwon DY; Kang YH; Lee KW; Park JH
    Br J Nutr; 2013 Jan; 109(2):210-22. PubMed ID: 22716951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.